Brightsurf Science News & Current Events

April 12, 2014
Gut microbiota may play a role in the development of alcoholic liver disease
Exciting new data presented today at the International Liver Congress 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease.

Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients
Three new studies presented today at the International Liver Congress 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues to achieve the best treatment outcomes in patients with chronic hepatitis B.

Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients
Results from an international Phase III study presented today at the International Liver Congress 2014 have shown obeticholic acid given to patients suffering from primary biliary cirrhosis who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid, produced meaningful biochemical and clinical improvements.

New Chinese herbal medicine has significant potential in treating hepatitis C
Data from a late-breaking abstract presented at the International Liver Congress 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus activity in cells at several points in the virus' lifecycle.

New combination drug therapy proves very effective in hepatitis C treatments
Treatment options for the 170 million people worldwide with chronic hepatitis C virus are evolving rapidly, although the available regimens often come with significant side effects.

New advances in HCC diagnosis, staging and treatment all predicted to improve patient outcomes
Epidemiological, genetic and clinical data presented today at the International Liver Congress 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma.

Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients
Results from three Phase III clinical trials evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir 400mg and the NS5A inhibitor ledipasvir 90mg, with and without ribavirin, for the treatment of genotype 1 chronic hepatitis C virus infection have been presented at the International Liver Congress 2014.

Hepatitis C treatment cures over 90 percent of patients with cirrhosis
Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients
The new interferon-free, all-oral, three direct-acting-antiviral treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1; according to the results of three studies presented today at the International Liver Congress 2014.

New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens
Results from RESTORE , a Phase III, multi-center, single-arm, open-label study presented today at the International Liver Congress 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients.

Low vitamin D linked to fatty liver disease in UK children
A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease in British children has identified a genetic variant associated with the disease's severity.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.